New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
11:33 EDTICPTIntercept trial of Obeticholic Acid posted on ClinicalTrials.gov
A trial of Intercept's Obeticholic Acid was posted on ClinicalTrials.gov, with a stated main purpose to test the drug' effectiveness when used in patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals with alcoholic hepatitis have certain abnormalities in how their body handles bile acids produced by the liver, the guidance said. Obeticholic acid has "been shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may improve liver condition in individuals with alcoholic hepatitis," the website notes. Shares of Intercept are up 10%, or $27.38, to $305.00 in late morning trading. Reference Link
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:59 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Subscribe for More Information
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Subscribe for More Information
April 9, 2014
07:23 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:03 EDTICPTPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use